Vesalius Biocapital Partners Research
Investment Thesis
Vesalius Biocapital Partners is a Luxembourg-based venture capital manager that invests in European companies active in human health. It has raised venture funds since 2007 and says it has helped develop about 20 companies. The strategy is focused on three areas: therapeutics, medical devices and diagnostics. It looks for sound proprietary technology with matching IP, unique team skills and a clear competitive edge based on solid data. The firm describes its team as seasoned life science professionals with deep scientific understanding and investment expertise, and it positions itself as more than a source of money.
Stage Focus
The firm invests in all stages of development and says it does not shy away from relatively early-stage projects. It finances both early-stage companies and corporate spin-offs with more mature assets. Its portfolio ranges from academic spin-offs to later-stage companies with products on the market, and recent activity includes a Series C financing (ENYO Pharma, 2025).
Check Size
The firm invests progressively over several financing rounds and may commit up to EUR 10 million in a single portfolio company. It may also put a few hundred thousand euro into a seed project. A June 2025 Series C investment in ENYO Pharma was EUR 6 million from Vesalius Biocapital IV.
Lead Tendency
Vesalius says it plays the role of lead investor in the large majority of its financing rounds. The about page says it leads or co-leads investments and will always hold a board seat.
Recent Activity and Funds
- Vesalius Biocapital III reached a final close of EUR 120 million in 2019 (first close of EUR 65 million in May 2017).
- Vesalius Biocapital IV announced a first close of EUR 95 million in June 2023, targeting EUR 150 million with rolling closes.
- June 2025: EUR 6 million Series C investment in ENYO Pharma from Fund IV.
- August 2025: PitchBook lists Rejuvenate Biomed as the latest investment of Fund III.
- The firm presented its investment strategy and 2026 priorities at a Paris-Saclay Cancer Cluster investor talk in September 2026.
The website's own claim of more than EUR 150 million under management in two funds appears to be out of date, since at least four funds now exist.
Portfolio Highlights
The portfolio page lists 21 companies, a mix of exits and active holdings.
- Exits include GenKyoTex (IPO on Euronext), Activaero, Amakem, Apitope, FF Pharmaceuticals, Fovea, Ogeda (formerly Euroscreen), ProFibrix, Skyline Diagnostics, Softhale, Trinean and Voluntis.
- Active companies include Bienca, Complix, Exact Imaging (micro-ultrasound for prostate cancer), Genomic Vision, Humedics, Ncardia (Pluriomics), Omeicos Therapeutics, Promethera and Trod Medical.
Team
- Gaston Matthyssens, PhD: Managing Partner
- Alain Parthoens: Managing Partner
- Christian Schneider, PhD: Managing Partner
- Stephane Verdood: Managing Partner
- Guy Geldhof: Partner
Decision Process
The firm is a partnership of managing partners and a partner. Public sources do not describe a formal investment committee process or decision timeline. It works with non-exclusive partnership agreements with Centres of Excellence, including VIB (Flanders Life Sciences Research Institute) and Fraunhofer, which supply deal flow and review of major R&D programs on a bi-yearly basis, and the partners assist the spin-off process and act as lead or co-lead investor when criteria are met.
Founder Preferences
The firm backs scientific teams with proprietary technology and IP, including university and research-institute spin-offs. It brings advice on the business plan, introductions to other venture investors and leading healthcare companies, help hiring talented people, and support with exit optimization. It always takes a board seat, so founders should expect an active, hands-on investor.
Geographic Focus
Portfolio companies are based in Europe, which the firm says allows easy interaction with management. Its deal flow comes from European research centres, notably in Belgium, Germany and France. The firm is headquartered at 1B rue Thomas Edison, 1445 Strassen, Luxembourg.